Ocular Therapeutix is a biopharmaceutical company that develops and commercializes therapies for diseases and conditions of the eye. The company's lead product candidate, DEXTENZA, is a corticosteroid that is used to treat post-surgical ocular inflammation and pain. Ocular Therapeutix was founded in 2006 and is headquartered in Bedford, Massachusetts. The company is publicly traded on the NASDAQ under the ticker symbol OCUL.
Learn more about Ocular Therapeutix